R
Rodney E. Shackelford
Researcher at LSU Health Sciences Center Shreveport
Publications - 54
Citations - 796
Rodney E. Shackelford is an academic researcher from LSU Health Sciences Center Shreveport. The author has contributed to research in topics: Nicotinamide phosphoribosyltransferase & Cancer. The author has an hindex of 13, co-authored 54 publications receiving 634 citations. Previous affiliations of Rodney E. Shackelford include Louisiana State University & Tulane University.
Papers
More filters
Journal ArticleDOI
Epigenetics in non-small cell lung cancer: from basics to therapeutics.
TL;DR: The molecular pathology of lung cancer epigenetic aberrations is summarized and current efforts to target the epigenome with different pharmacological approaches are discussed, with main focus on hypomethylating agents, histone deacetylase (HDAC) inhibitors, microRNA modulations, and the role of novel epigenetic biomarkers.
Journal ArticleDOI
Nicotinamide phosphoribosyltransferase in malignancy: a review.
TL;DR: The roles of Nampt in malignancy, some of the known mechanisms by which it promotes carcinogenesis, and the possibility of employing Nampt inhibitors in cancer treatment are reviewed.
Journal ArticleDOI
ALK-rearrangements and testing methods in non-small cell lung cancer: a review.
TL;DR: This work reviews ALKmediated signal transduction pathways and compares the molecular protocols used to identify dysregulated ALK expression in NSCLC, and discusses the use of crizotinib and second generation ALK tyrosine kinase inhibitors in the treatment of ALK positiveNSCLC.
Journal ArticleDOI
Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment.
Junaid Ansari,Abdul Rafeh Naqash,Abdul Rafeh Naqash,Reinhold Munker,Hazem E El-Osta,Samip Master,James D. Cotelingam,Elizabeth A. Griffiths,Adam H. Greer,Hong Yin,Prakash Peddi,Rodney E. Shackelford +11 more
TL;DR: The concurrent expression of immunoglobulin heavy (IGH)‐/light‐chain rearrangements or cytogenetic markers common to the primary malignancy suggests an evolutionary mechanism involving lineage switching that could potentially be influenced by genetic or epigenetic cues which may occur at the level of a progenitor or the malignant cell itself.
Journal ArticleDOI
KRAS Testing: A Tool for the Implementation of Personalized Medicine.
TL;DR: This review found that several different methods are used for clinical KRAS mutation testing, and information is provided about their performance, cost, turnaround times, detection limits, sensitivities, and specificities.